Navitoclax ABT-263

Size	Price	Stock	Quantity
Get Quotation Now Add to Cart Bulk Inquiry

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

Chemical Information

Product name：Navitoclax ABT-263	Purity：98% min
CAS NO：923564-51-6	Solubility：DMSO : 75 mg/mL (76.95 mM)
Molecular Formula：C₄₇H₅₅ClF₃N₅O₆S₃	Package：Package according to customer requirements
Molecular Weight：974.613	Storage：Store at -20℃

Quality control

COA

Remarks

Navitoclax, also known as ABT-263, is an orally bioavailable, synthetic small-molecule antagonist of a subset of the B-cell leukemia 2 (Bcl-2) family of proteins with potential antineoplastic activity. ABT-263 selectively binds to apoptosis suppressor proteins Bcl-2, Bcl-XL, and Bcl-w and prevents their binding to the apoptotic effectors Bax and Bak proteins, which may trigger apoptosis in tumor cells overexpressing Bcl-2, Bcl-XL, and Bcl-w.

Bcl-2 Inhibitors Related Products:

ABT-737; Obatoclax Mesylate; Venetoclax; HA14-1; S63845; UMI-77; Mifepristone

References

[1]. Lock R1, et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Jun;50(6):1181-1189.

[2]. Wong M, et al. Navitoclax (ABT-263) reduces Bcl-x(L)-mediated chemoresistance in ovarian cancer models.Mol Cancer Ther. 2012 Apr;11(4):1026-1035.